3 results
Approved WMOCompleted
The objective of this study is to evaluate the effect of the 4 successive monthly subcutaneous administrations of 30 mg of gevokizumab (in part A) , as well as 60mg (in part B) of the protocol, versus placebo on the reduction of arterial wall…
Approved WMOCompleted
The objective of this study is to explore the efficacy and safety of gevokizumab in patients with Schnitzler syndrome.
Approved WMOCompleted
to study the effect of therapeutic dose of corticosteroids, administered via nasal spray and inhalation for 28 days, on strength in strength athletes and on maximal power output in cyclists.